neurotranslation:
Our PRESS RELEASES
A selection of press releases about the NeuroTranslational Drug Discovery Program
JHU enters into broad drug discovery collaboration with Eisai
The Johns Hopkins University has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer’s disease. Licensing Agreement with Pharmaceutical Company Eisai Inc.
Brain Science Institute Announces License Agreement to Develop New Treatments for Neurological Disease Neuronascent Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs
Neuronascent, Inc. announced today that the Company has received funding from both the federal government, under the Qualifying Therapeutic Discovery Project for the development of its preclinical therapeutic candidates for neurodegenerative diseases, and from Maryland’s Biotechnology Center, to accelerate development of its neurogenic candidate for Down syndrome. The latter project is a collaboration with Dr. Barbara Slusher, Chief Scientific Officer, Johns Hopkins University’s NeuroTranslational Brain Center. Cancer Cells Feed on Sugar-Free Diet
Study highlights role of glutamine in absence of glucose in growth of B cell tumors. Cancer cells have been long known to have a “sweet tooth,” using vast amounts of glucose for energy and for building blocks for cell replication.
Study Sheds Light on How Palonosetron Prevents Delayed CINV
Palonosetron (Aloxi) is the only 5-HT3 receptor antagonist approved for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) following administration of moderately emetogenic chemotherapeutic agents.
The Johns Hopkins University has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer’s disease. Licensing Agreement with Pharmaceutical Company Eisai Inc.
Brain Science Institute Announces License Agreement to Develop New Treatments for Neurological Disease Neuronascent Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs
Neuronascent, Inc. announced today that the Company has received funding from both the federal government, under the Qualifying Therapeutic Discovery Project for the development of its preclinical therapeutic candidates for neurodegenerative diseases, and from Maryland’s Biotechnology Center, to accelerate development of its neurogenic candidate for Down syndrome. The latter project is a collaboration with Dr. Barbara Slusher, Chief Scientific Officer, Johns Hopkins University’s NeuroTranslational Brain Center. Cancer Cells Feed on Sugar-Free Diet
Study highlights role of glutamine in absence of glucose in growth of B cell tumors. Cancer cells have been long known to have a “sweet tooth,” using vast amounts of glucose for energy and for building blocks for cell replication.
Study Sheds Light on How Palonosetron Prevents Delayed CINV
Palonosetron (Aloxi) is the only 5-HT3 receptor antagonist approved for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) following administration of moderately emetogenic chemotherapeutic agents.
